Recent regulatory decisions and industry trends reflect evolving dynamics in biotech. The U.S. court has halted sweeping HHS layoffs deemed likely unlawful, impacting agencies including FDA and CDC amid concerns over drug approval delays. CMS established reimbursement for Eko Health’s AI cardiac diagnosis platform. Nordic Capital acquired data platform Arcadia to accelerate value-based care. Several companies, including 4D Molecular Therapeutics and Vor Bio, reshuffle leadership and funding strategies to navigate the challenging market. IPO activity and M&A persist with investors eyeing biotech opportunities amid a complex environment.